Jianli Zhao1,2, Yajing Wang1, Dajie Wang3. 1. Department of Emergency Medicine, Thomas Jefferson University, Philadelphia, USA. 2. Department of Anesthesiology, Shanxi Medical University, Taiyuan, Shanxi, China. 3. Jefferson Pain Center, Department of Anesthesiology, Thomas Jefferson University, Philadelphia, USA. Dajie.Wang@jefferson.edu.
Abstract
PURPOSE OF REVIEW: Complex regional pain syndrome (CRPS) is a painful debilitating neurological condition that accounts for approximately 1.2% of adult chronic pain population. Ketamine, an NMDA receptor antagonist, is an anesthetic agent that has been used by some pain specialists for CRPS. There is a growing body of clinical evidence to support the use of ketamine in the treatment of neuropathic pain, especially CRPS. This meta-analysis study was aimed to examine the efficacy of ketamine in the treatment of CRPS. RECENT FINDINGS: A search of Embase, Pubmed, Web of Knowledge, Cochrane, Clinical Trial.gov , and FDA.gov between Jan 1, 1950, and August 1, 2017, was conducted to evaluate ketamine infusion therapy in the treatment of CRPS. We selected randomized clinical trials or cohort studies for meta-analyses. I 2 index estimates were calculated to test for variability and heterogeneity across the included studies. The primary outcome is pain relief. The effect of ketamine treatment for complex regional pain syndrome was assessed by 0-10 scale numerical rating pain score. The secondary outcome is the pain relief event rate, which is defined as the percentage of participants who achieved 30% or higher pain relief in each of the qualified studies. Our meta-analysis results showed that the Ketamine treatment led to a decreased mean of pain score in comparison to the self-controlled baseline (p < 0.000001). However, there is a statistical significance of between-study heterogeneity. The immediate pain relief event rate was 69% (95% confidence interval (CI) 53%, 84%). The pain relief event rate at the 1-3 months follow-ups was 58% (95% CI 41%, 75%). The current available studies regarding ketamine infusion for CRPS were reviewed, and meta-analyses were conducted to evaluate the efficacy of ketamine infusion in the treatment of CRPS. Our findings suggested that ketamine infusion can provide clinically effective pain relief in short term for less than 3 months. However, because of the high heterogeneity of the included studies and publication bias, additional random controlled trials and standardized multicenter studies are needed to confirm this conclusion. Furthermore, studies are needed to prove long-term efficacy of ketamine infusion in the treatment of CRPS.
PURPOSE OF REVIEW: Complex regional pain syndrome (CRPS) is a painful debilitating neurological condition that accounts for approximately 1.2% of adult chronic pain population. Ketamine, an NMDA receptor antagonist, is an anesthetic agent that has been used by some pain specialists for CRPS. There is a growing body of clinical evidence to support the use of ketamine in the treatment of neuropathic pain, especially CRPS. This meta-analysis study was aimed to examine the efficacy of ketamine in the treatment of CRPS. RECENT FINDINGS: A search of Embase, Pubmed, Web of Knowledge, Cochrane, Clinical Trial.gov , and FDA.gov between Jan 1, 1950, and August 1, 2017, was conducted to evaluate ketamine infusion therapy in the treatment of CRPS. We selected randomized clinical trials or cohort studies for meta-analyses. I 2 index estimates were calculated to test for variability and heterogeneity across the included studies. The primary outcome is pain relief. The effect of ketamine treatment for complex regional pain syndrome was assessed by 0-10 scale numerical rating pain score. The secondary outcome is the pain relief event rate, which is defined as the percentage of participants who achieved 30% or higher pain relief in each of the qualified studies. Our meta-analysis results showed that the Ketamine treatment led to a decreased mean of pain score in comparison to the self-controlled baseline (p < 0.000001). However, there is a statistical significance of between-study heterogeneity. The immediate pain relief event rate was 69% (95% confidence interval (CI) 53%, 84%). The pain relief event rate at the 1-3 months follow-ups was 58% (95% CI 41%, 75%). The current available studies regarding ketamine infusion for CRPS were reviewed, and meta-analyses were conducted to evaluate the efficacy of ketamine infusion in the treatment of CRPS. Our findings suggested that ketamine infusion can provide clinically effective pain relief in short term for less than 3 months. However, because of the high heterogeneity of the included studies and publication bias, additional random controlled trials and standardized multicenter studies are needed to confirm this conclusion. Furthermore, studies are needed to prove long-term efficacy of ketamine infusion in the treatment of CRPS.
Authors: Michael E Goldberg; Marc C Torjman; Robert J Schwartzman; Donald E Mager; Irving W Wainer Journal: Pain Physician Date: 2010 Jul-Aug Impact factor: 4.965
Authors: Johanna C M Schilder; Marnix J Sigtermans; Alfred C Schouten; Hein Putter; Albert Dahan; Lucas P J J Noldus; Johan Marinus; Jacobus J van Hilten Journal: J Pain Date: 2013-09-24 Impact factor: 5.820
Authors: M de Mos; A G J de Bruijn; F J P M Huygen; J P Dieleman; B H Ch Stricker; M C J M Sturkenboom Journal: Pain Date: 2006-11-07 Impact factor: 6.961
Authors: Marnix J Sigtermans; Jacobus J van Hilten; Martin C R Bauer; Sesmu M Arbous; Johan Marinus; Elise Y Sarton; Albert Dahan Journal: Pain Date: 2009-07-14 Impact factor: 6.961
Authors: Sandra P Koffler; Benjamin M Hampstead; Farzin Irani; Jennifer Tinker; Ralph-Thomas Kiefer; Peter Rohr; Robert J Schwartzman Journal: Arch Clin Neuropsychol Date: 2007-07-03 Impact factor: 2.813
Authors: Ralph-Thomas Kiefer; Peter Rohr; Annette Ploppa; Boris Nohé; Hans-Jürgen Dieterich; John Grothusen; Karl-Heinz Altemeyer; Klaus Unertl; Robert J Schwartzman Journal: Pain Med Date: 2008 Jan-Feb Impact factor: 3.750
Authors: Kathy A Sheehy; Elena A Muller; Caroline Lippold; Mehdi Nouraie; Julia C Finkel; Zenaide M N Quezado Journal: BMC Pediatr Date: 2015-12-01 Impact factor: 2.125
Authors: Alyson R Plecash; Amokrane Chebini; Alvin Ip; Joshua J Lai; Andrew A Mattar; Jason Randhawa; Thalia S Field Journal: Curr Neurol Neurosci Rep Date: 2019-11-13 Impact factor: 5.081
Authors: Xiaofeng Lan; Yanling Zhou; Chengyu Wang; Weicheng Li; Fan Zhang; Haiyan Liu; Ling Fu; Kai Wu; Roger S McIntyre; Yuping Ning Journal: Front Psychiatry Date: 2022-03-16 Impact factor: 4.157
Authors: Thomas J P Mangnus; Maaike Dirckx; Krishna D Bharwani; Cecile C de Vos; Sander P G Frankema; Dirk L Stronks; Frank J P M Huygen Journal: Pain Pract Date: 2021-07-24 Impact factor: 3.079
Authors: Samantha Cotter; Jennie Wong; Neha Gada; Rajdeep Gill; S Christopher Jones; Grace Chai; Daniel Foster; Mark Avigan; Mallika Mundkur Journal: Drug Saf Date: 2021-10-26 Impact factor: 5.606